Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
AssigneeBoehringer Ingelheim Internation GmbH
InventorsThomas KLEIN, Maximilian von EYNATTEN, Michael MARK
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for treating and/or preventing podocytes related disorders and/or nephrotic syndrome comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and/or preventing a metabolic disease in a patient with or at risk of podocytes related disorders and/or nephrotic syndrome.
Claims3
A method of preventing, reducing the risk of or delaying the onset or progression micro- or macro-albuminaria, the onset of chronic kidney disease (CKD), the worsening of CKD, the onset of acute renal failure or death in a human type 2 diabetes patient, said method comprising administering linagliptin in a daily oral amount of 5 mg to the patient.
Dependencies are inferred from the claim text.